Analysts’ recommendations and target price
Wall Street analysts expect a potential upside of 2.45% for United Therapeutics (UTHR) based on the stock’s closing price on March 21.
Analysts revised the company’s target price upward from $125.27 in January and February to $126.00 in March. The current consensus analyst recommendation for the stock is a “hold.”
Of the 12 analysts covering United Therapeutics, two have given it “strong buys,” five have given it “holds,” four have given it “sells,” and one has given it a “strong sell.” The highest target price estimate for the company is $269, and the lowest is $95.
On March 21, United Therapeutics closed at $122.99, 1.44% higher than its previous closing price, 22.92% higher than its 52-week low of $100.06, and 5.39% lower than its 52-week high of $130.00. The company’s market cap is $5.34 billion.
Based on its closing price on March 21, United Therapeutics has reported returns of 5.09% in the last week, 4.33% in the last month, and 15.92% in the last quarter. The company has reported returns of -2.54% in the last half year, 14.19% in the last year, and 12.94% year-to-date.
In its fourth quarter, United Therapeutics reported revenue of $381.40 million, a YoY (year-over-year) fall of 17.93% but $25.59 million higher than the consensus estimate. The company reported non-GAAP (generally accepted accounting principles) EPS of $3.34, a YoY fall of 14.14% but still $0.79 higher than the consensus estimate. According to the company’s fourth-quarter earnings conference call, the loss of patent protection for Adcirca negatively affected its 2018 revenue performance.
Analysts expect United Therapeutics’ revenue to see YoY falls of -14.22% to $333.86 million in the first quarter, -26.90% to $324.92 million in the second quarter, -26.42% to $303.68 million in the third quarter, and -19.78% to $305.97 million in the fourth quarter of 2019. They expect United Therapeutics’ revenue to see YoY falls of -20.89% to $1.29 billion in 2019, -7.82% to $1.19 billion in 2020, and -3.17% to $1.15 billion in 2021.
Next, we’ll discuss analysts’ recommendations and projections for Jazz Pharmaceutical.